These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37422012)

  • 41. Drugs to interfere with orexins (hypocretins).
    Selbach O; Eriksson KS; Haas HL
    Drug News Perspect; 2003 Dec; 16(10):669-81. PubMed ID: 14747847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypocretin/orexin and narcolepsy: new basic and clinical insights.
    Nishino S; Okuro M; Kotorii N; Anegawa E; Ishimaru Y; Matsumura M; Kanbayashi T
    Acta Physiol (Oxf); 2010 Mar; 198(3):209-22. PubMed ID: 19555382
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy.
    Baumann CR; Khatami R; Werth E; Bassetti CL
    J Neurol Neurosurg Psychiatry; 2006 Mar; 77(3):402-4. PubMed ID: 16484654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Autoimmune mechanisms and new opportunities for treatment narcolepsy].
    Medvedeva AV; Golovatyuk AO; Poluektov MG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(4. Vyp. 2):56-62. PubMed ID: 31317916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy.
    Weinhold SL; Seeck-Hirschner M; Nowak A; Hallschmid M; Göder R; Baier PC
    Behav Brain Res; 2014 Apr; 262():8-13. PubMed ID: 24406723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Narcolepsy and orexins: an example of progress in sleep research.
    De la Herrán-Arita AK; Guerra-Crespo M; Drucker-Colín R
    Front Neurol; 2011; 2():26. PubMed ID: 21541306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Narcolepsy.
    Barateau L; Pizza F; Plazzi G; Dauvilliers Y
    J Sleep Res; 2022 Aug; 31(4):e13631. PubMed ID: 35624073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An overview of hypocretin based therapy in narcolepsy.
    Takenoshita S; Sakai N; Chiba Y; Matsumura M; Yamaguchi M; Nishino S
    Expert Opin Investig Drugs; 2018 Apr; 27(4):389-406. PubMed ID: 29623725
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Orexins: effects on behavior and localisation of orexin receptor 2 messenger ribonucleic acid in the rat brainstem.
    Sunter D; Morgan I; Edwards CM; Dakin CL; Murphy KG; Gardiner J; Taheri S; Rayes E; Bloom SR
    Brain Res; 2001 Jul; 907(1-2):27-34. PubMed ID: 11430882
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A circuit perspective on narcolepsy.
    Adamantidis AR; Schmidt MH; Carter ME; Burdakov D; Peyron C; Scammell TE
    Sleep; 2020 May; 43(5):. PubMed ID: 31919524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy.
    Williams RH; Tsunematsu T; Thomas AM; Bogyo K; Yamanaka A; Kilduff TS
    J Neurosci; 2019 Nov; 39(47):9435-9452. PubMed ID: 31628177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The physiological role of orexins.
    Martynska L; Wolinska-Witort E; Chmielowska M; Bik W; Baranowska B
    Neuro Endocrinol Lett; 2005 Aug; 26(4):289-92. PubMed ID: 16135995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients.
    Lin JS; Dauvilliers Y; Arnulf I; Bastuji H; Anaclet C; Parmentier R; Kocher L; Yanagisawa M; Lehert P; Ligneau X; Perrin D; Robert P; Roux M; Lecomte JM; Schwartz JC
    Neurobiol Dis; 2008 Apr; 30(1):74-83. PubMed ID: 18295497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypocretin (orexin) deficiency in narcolepsy and primary hypersomnia.
    Ebrahim IO; Sharief MK; de Lacy S; Semra YK; Howard RS; Kopelman MD; Williams AJ
    J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):127-30. PubMed ID: 12486284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism.
    Dugovic C; Shelton JE; Yun S; Bonaventure P; Shireman BT; Lovenberg TW
    Front Neurosci; 2014; 8():28. PubMed ID: 24592208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders.
    Xu TR; Yang Y; Ward R; Gao L; Liu Y
    Cell Signal; 2013 Dec; 25(12):2413-23. PubMed ID: 23917208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypocretin and its emerging role as a target for treatment of sleep disorders.
    Cao M; Guilleminault C
    Curr Neurol Neurosci Rep; 2011 Apr; 11(2):227-34. PubMed ID: 21170610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brain Circuits Underlying Narcolepsy.
    Pintwala SK; Peever J
    Neuroscientist; 2023 Dec; 29(6):751-766. PubMed ID: 34704497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Orexin receptors: Structural and anti-tumoral properties.
    Couvineau A; Nicole P; Gratio V; Voisin T
    Front Endocrinol (Lausanne); 2022; 13():931970. PubMed ID: 35966051
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice.
    Mieda M; Willie JT; Hara J; Sinton CM; Sakurai T; Yanagisawa M
    Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4649-54. PubMed ID: 15070772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.